anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Mutations in the KLHL40 gene are a common cause of severe or even lethal nemaline myopathy. Some cases with mild forms have been described, although the cases are still anecdotal. The aim of this paper was to systematically review the cases described in the literature and to describe a 12-year clinical and imaging follow-up in an Italian patient with KLHL40- related myopathy in order to suggest possible follow-up measurements.
METHODS: Having searched through three electronic databases (PubMed, Scopus, and EBSCO), 18 articles describing 65 patients with homozygous or compound heterozygous KLHL40 mutations were selected. A patient with a KLHL40 homozygous mutation (c.1582G>A/p.E528K) was added and clinical and genetic data were collected.
RESULTS: The most common mutation identified in our systematic review was the (c.1516A>C) followed by the (c.1582G>A). In our review, 60% percent of the patients died within the first 4 years of life. Clinical features were similar across the sample. Unfortunately, however, there is no record of the natural history data in the surviving patients. The 12-year follow-up of our patient revealed a slow improvement in her clinical course, identifying muscle MRI as the only possible marker of disease progression.
CONCLUSIONS: Due to its clinical and genotype homogeneity, KLHL40-related myopathy may be a condition that would greatly benefit from the development of new gene therapies; muscle MRI could be a good biomarker to monitor disease progression.
In controlled trials ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. 

Angioedema of the face, extremities, lips, tongue, glottis, and larynx has been reported in patients treated with ACE inhibitors including trandolapril tablets. Symptoms suggestive of angioedema or facial edema occurred in 0.13% of trandolapril tablets-treated patients. Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). Angioedema associated with laryngeal edema can be fatal. If laryngeal stridor or angioedema of the face, tongue or glottis occurs, treatment with trandolapril tablets should be discontinued immediately, the patient treated in accordance with accepted medical care and carefully observed until the swelling disappears. In instances where swelling is confined to the face and lips, the condition generally resolves without treatment; antihistamines may be useful in relieving symptoms. Where there is involvement of the tongue, glottis, or larynx, likely to cause airway obstruction, emergency therapy, including but not limited to subcutaneous epinephrine solution 1:1,000 (0.3 to 0.5 mL) should be promptly administered. (See PRECAUTIONS \- Information for Patients and ADVERSE REACTIONS.) 

Patients receiving coadministration of an ACE inhibitor with an mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) may be at increased risk for angioedema.
Adolescents will participate in a 6-month intensive lifestyle modification that includes a structured exercise program, nutrition education and dietary modification and behavioral support, followed by a 6-month maintenance phase with monthly booster sessions. Parents will be randomized to participate in 4 dedicated "pre-treatment" parent psychoeducational sessions vs. control (no psychoeducational sessions). The sessions will explore parents' feelings about participation in a weight management program, explore their reasons for wanting to make behavioral changes, and enhance motivation. All parents will participate in monthly parent support groups while their adolescents are participating in the intervention phase of the study. The 6-month adolescent intervention will include biweekly sessions with a registered dietitian for dietary education; biweekly interactive group discussion sessions on topics pertaining to motivation, strategies for changing health behaviors, setting and keeping goals and dealing with peer pressure; and exercise sessions three times a week with 30 minutes of cardiovascular exercise and 30 minutes of strength training each session. Comprehensive assessments, including nutrition, behavior and exercise assessments, laboratory work, body composition measurements and medical assessments will be conducted at baseline, 6 months and 12 months.
A method and apparatus provides for the formation of compression dosage units from tableting feedstock. A feedstock dossiter is provided including an open ended chamber for insertion into a reservoir containing the tableting feedstock. The dossiter includes a movable die punch which is movable within the chamber between at least two positions. A first position away from the open end of the chamber provides for the collection of a preselected volume of tableting feedstock from the reservoir. The die punch is movable to a second position which effects formation of the tablet within the accumulation chamber. The dossiter shown herein may be used in combination with a fixed die punch to form the tablet.
The patient will receive 15 sessions of the Global Postural Re-education approach performed 2times/week for 1 hour including patient education. Each treatment will be individualized for every patient and for his/her pain-related limitation. Each session includes only 2-3 postures to increase the standardization of treatment.
Methods, systems, and devices for content delivery are described. A device may receive biometric data associated with a user from a wearable device, and receive application data associated with the user from the device. The application data may be indicative of a previous activity in which the user engaged or an upcoming activity in which the user is to engage. The device may determine content for recommending to the user based on correlating the received biometric data and the received application data. The content may correspond to a respective effectiveness for regulating the received biometric data. In some examples, the content may facilitate improvements to the user’s health and wellness. The device may cause a graphical user interface (GUI) of the device running an application to display the content for recommending to the user based on correlating the received biometric data and the received application data.
BACKGROUND: Whether intensive glucose control reduces mortality in critically ill patients remains uncertain. Patient-level meta-analyses can provide more precise estimates of treatment effects than are currently available.
METHODS: We pooled individual patient data from randomized trials investigating intensive glucose control in critically ill adults. The primary outcome was in-hospital mortality. Secondary outcomes included survival to 90 days and time to live cessation of treatment with vasopressors or inotropes, mechanical ventilation, and newly commenced renal replacement. Severe hypoglycemia was a safety outcome.
RESULTS: Of 38 eligible trials (n=29,537 participants), 20 (n=14,171 participants) provided individual patient data including in-hospital mortality status for 7059 and 7049 participants allocated to intensive and conventional glucose control, respectively. Of these 1930 (27.3%) and 1891 (26.8%) individuals assigned to intensive and conventional control, respectively, died (risk ratio, 1.02; 95% confidence interval [CI], 0.96 to 1.07; P=0.52; moderate certainty). There was no apparent heterogeneity of treatment effect on in-hospital mortality in any examined subgroups. Intensive glucose control increased the risk of severe hypoglycemia (risk ratio, 3.38; 95% CI, 2.99 to 3.83; P<0.0001).
CONCLUSIONS: Intensive glucose control was not associated with reduced mortality risk but increased the risk of severe hypoglycemia. We did not identify a subgroup of patients in whom intensive glucose control was beneficial. (Funded by the Australian National Health and Medical Research Council and others; PROSPERO number CRD42021278869.).
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multi organ hypersensitivity, has occurred with Zarontin. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy and/or facial swelling, in association with other organ system involvement, such as hepatitis, nephritis, hematologic abnormalities, myocarditis, or myositis, sometimes resembling an acute viral infection. Eosinophilia is often present. This disorder is variable in its expression, and other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity (e.g. fever, lymphadenopathy) may be present even though rash is not evident. If such signs or symptoms are present, the patient should be evaluated immediately. Zarontin should be discontinued if an alternative etiology for the signs or symptoms cannot be established.
A predictive model can be applied to data representing a history of events for an entity to compute a value indicative of an outcome related to a reference time for that entity. The effect of an event from an entity's history of events on an outcome for the entity at a reference time can vary based on the type of event and relative time of that event with respect to the reference time. The effect of an event from an entity's history of events on an outcome for the entity also can vary due to other characteristics of the entity in combination with the event. These effects are captured as weights. For an entity, functions of sets of events from the history of events are computed for the entity and a set of weights for events. The computed results are inputs to the predictive model.
PURPOSE:To produce the subject compound on an industrial scale at a low cost by allowing a sugar transferase to act upon a rutin-rich liquid containing rutin and starch at high concentrations. CONSTITUTION:Rutin is dissolved at a concentration of >=0.5w/v% in an aqueous solution of an organic solvent containing methanol, etc., a starchy substance such as amylose is added to the solution in an amount of 0.5-50 pts. per 1 pt. of rutin, a sugar transferase such as alpha-amylase is added to the mixture and the components are made to react with each other at pH4.5-6.5 and 70-90 deg.C for 5-80hrs to obtain a reaction product containing a large amount of alpha-glucosyl rutin and a small amount of unreacted rutin and having a total rutin content of 1-20w/v% in terms of rutin. The reaction product is purified with a porous synthetic adsorbent resin and treated with beta-amylase to form alpha-glucosyl rutin and/or alpha-maltosyl rutin, from which alpha-glucosyl rutin is collected. As necessary, the rutin is used as an active component of a remedy for sensitive diseases.
The patient will be admitted to hospital for placement of the nasogastric tube and commencement of exclusive enteral nutrition (EEN). Nutritional feeds will consist of a semi-elemental (whey-peptide based) formula that will make up all of the patient's daily caloric needs (120% of BMR). Feeds will slowly be titrated up to full volume and strength during the hospital stay. The patient will receive instructions how to decrease the number of hours of feeds once at home. The patient will be seen in clinic at two weeks and will receive a phone call from the dietician at 4 weeks to assess progress and symptom improvement. At 8 weeks, food will start to be reintroduced slowly, as per the dietician's instructions.
It is recommended that treatment starts with tazarotene gel, 0.05%, with strength increased to 0.1% if tolerated and medically indicated. Apply a thin film (2 mg/cm 2) of tazarotene gel once per day, in the evening, to cover only the psoriatic lesions on no more than 20% of body surface area. If a bath or shower is taken prior to application, the skin should be dry before applying the gel. If emollients are used, they should be applied at least an hour before application of tazarotene gel. Because unaffected skin may be more susceptible to irritation, application of tazarotene to these areas should be carefully avoided. Tazarotene gel was investigated for up to 12 months during clinical trials for psoriasis.
Our study, conducted between April 2022 and January 2024, was aimed at clarifying components of the rest-activity rhythm (RAR) involved in improvement of social frailty state before or after a 3-month multi-component exercise intervention in the elderly. Participants were recruited from the general population in Akita prefecture, Japan. We administered a four-item social frailty screening questionnaire to classify the severity of social frailty in each participant before and after the 3-month intervention. The RAR parameters were measured on an Actiwatch Spectrum Plus device worn by the subjects for 7 continuous days. As the final sample, 65 participants classified into the improved/maintained group (n = 36) or the deteriorated group (n = 29) according to the change in the social frailty classification after the intervention were included in the analysis. The results of a binomial logistic regression analysis showed significantly higher values of interdaily stability (IS) and usual walking speed at the post-test after the intervention. Based on our findings, we propose that stability of the rest-activity rhythm related to synchronization with external stimuli (such as social effect and physical activity) might have clinical impact on improvement of social frailty state in elderly community-dwellers.
OBJECTIVE: Psychometric studies evaluating the reliability of eating-disorder assessment among individuals with binge-eating disorder (BED) have been limited. The current study documents the interrater reliability and internal consistency of the Eating Disorder Examination (EDE) interview when administered to adults with Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5)-defined BED.
METHODS: Participants (N = 56) were adults seeking treatment for BED in the context of clinical trials testing pharmacological and psychological treatments. Doctoral-level, trained, and supervised clinical researchers evaluated eating-disorder psychopathology using the EDE interview and audio-recorded the interview. A second doctoral-level, trained, and supervised clinical researcher, who did not conduct the initial assessment, coded eating-disorder psychopathology using the audio recording.
RESULTS: Agreement among raters on the number of binge-eating episodes was near perfect. There was excellent interrater reliability for nearly all scales of the EDE interview. Agreement among raters for behavioral indicators of loss of control and marked distress regarding binge eating ranged from moderate to perfect. Internal consistency was variable for all scales, ranging from unacceptable to good.
CONCLUSIONS: Our study suggests that the EDE can be administered reliably by multiple interviewers to assess adults with BED. However, internal consistency was mostly subpar. Tests of reliability and other psychometric properties (e.g., validity) in other patient groups such as children with BED are warranted.
Thymocyte development requires precise control of PI3K-Akt signaling to promote proliferation and prevent leukemia and autoimmune disorders. Here, we show that ablating individual clusters of the miR-17∼92 family has a negligible effect on thymocyte development, while deleting the entire family severely impairs thymocyte proliferation and reduces thymic cellularity, phenocopying genetic deletion of Dicer. Mechanistically, miR-17∼92 expression is induced by Myc-mediated pre-T cell receptor (TCR) signaling, and miR-17∼92 promotes thymocyte proliferation by suppressing the translation of Pten. Retroviral expression of miR-17∼92 restores the proliferation and differentiation of Myc-deficient thymocytes. Conversely, partial deletion of the miR-17∼92 family significantly delays Myc-driven leukemogenesis. Intriguingly, thymocyte-specific transgenic miR-17∼92 expression does not cause leukemia or lymphoma but instead aggravates skin inflammation, while ablation of the miR-17∼92 family ameliorates skin inflammation. This study reveals intricate roles of the miR-17∼92 family in balancing thymocyte development, leukemogenesis, and autoimmunity and identifies those microRNAs (miRNAs) as potential therapeutic targets for leukemia and autoimmune diseases.
In the arm-cranking condition, the patients will perform fifteen bouts of two minutes of arm-cranking with an interval of two minutes between bouts, at an intensity equivalent to 13-15 on Borg's subjective perceived exertion scale. The condition will have a total of sixty minutes of duration.
<P>PROBLEM TO BE SOLVED: To provide a moisture-retaining plant extract retaining the moisture-retaining effects for a long time; and to provide an external preparation, a cosmetic, a bathing agent and a detergent.  <P>SOLUTION: The moisture-retaining plant extract consists of an extract of a mixture of Cinnamomum cassia Blume, Paeonia lactiflora Pallas, Prunus persica Batsch var. davidiana Maximowicz, Poria cocos Wolf, Paeonia suffruticosa Andrews (Paeonia moutan Sims), Grycyrrhiza glabra Linne and Zingiber officinale Rosco. The external preparation, the cosmetic, the bath salt and the detergent contain each the extract. A product obtained by decocting the above crude medicines in prescribed proportions has the same composition as a Chinese medicine called Kojito and exhibiting effects on irregularity of menstruation, menstruation disorder, menstrual colic, menopausal disorders, women's dizziness, shoulder discomfort, dizziness, dull headache, bruise, frostbite and liver spot by oral administration. The extract of these crude medicines contains a moisture-retaining plant component retaining the moisture-retaining effects for a long time, and exhibits the effects on the prevention, reduction or amelioration of dewatering, rough skin, cracks on the skin, chap on the skin, scurf, itching and inflammatory diseases of the skin, and on dryness, looseness, split hair, broken hair and impartation of gloss to the hair.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Transient osteoporosis of the hip (TOH) is an important but often neglected cause of hip pain, which can gradually lead to debilitating mobility and carries risks such as fracture or avascular necrosis. A 39-year-old woman presented to the Rheumatology department two weeks post-cesarean delivery, reporting the onset of left mechanical hip pain since the 33rd week of pregnancy. After delivery, similar complaints emerged on the right side. Hip X-ray showed a decrease in bone density in the left hip. Later, Magnetic Resonance Imaging revealed bilateral bone marrow edema in both proximal femurs. The diagnosis of TOH was established, and the patient was treated with conservative measures. Seven months later, she was asymptomatic. Pregnancy is a recognized risk factor for TOH, especially in the last trimester. It is an important differential diagnosis to consider in cases of hip pain in pregnant or newly breastfeeding women.
Participants in the randomized trial will be 300 mothers of 3-5 year old children recruited through Head Start (HS) classrooms and screened for the presence of major or minor depression. Subsequent to the pre-intervention assessment, participants will be randomized, with an allocation ratio of 1:1, to either the Mom-Net (MN) intervention or facilitated usual care (FUC) condition. Participants in the MN condition will receive the Mom-Net intervention. The Mom-Net program is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Participants in both conditions will receive Booster calls during the follow-up period.
Encorafenib 450 mg. p.o.once daily and Binimetinib 45 mg p.o. twice daily until disease progression or toxicity requiring discontinuation of treatment. 1 cycle is defined as 28 days.
Adult women aged over 18 years old with pain during more than six months are included in the study. These patients will receive a global posture reeducation.
PURPOSE:To provide a titled gold alloy which prevents blacking of the casting surface of a casting, has an excellent yellowish color, resistance to discoloration and mechanical strength and is easy to work, by consisting the same of gold, palladium, indium, zinc and silver in a specific compsn. but excluding copper. CONSTITUTION:A gold alloy which is highly resistant to discoloration under various conditions such as in the atmosphere, in contact with human skin, in the mouth or the like, has mechanical strength, has a yellowish color equivalent to about 14-18K and is suited for dental purposes, decorative and ormanental purposes, etc. is obtd. of a low karat gold alloy contg. 0.5-42wt% gold, 5-35% palladium, 18-30% indium, 0.1-10% zinc and the balance silver. For the limits in the range of the respective components of the above-mentioned alloy, gold is in the range of a low karat gold alloy, palladium is in the amt. required for improving strength and corrosion resistance and zinc is the amt. required as a deoxidizing agent. Indium improves mechanical strength, and the resistance to discoloration and corrosion, prevents the blacking of the casting surface of a casting and provides a remarkable yellowish color.
Tumor specimens removed from 20 women with ovarian cancer are injected into 40 mice treated with the IGF1R antibody MK-0646. The drug will be administered twice weekly, via IP injection at a dose of 500 microgram per animal.
The invention relates to a traditional Chinese medicinal preparation for adjuvant therapy of depression and a preparation method thereof. Effective components of the traditional Chinese medicinal preparation comprise the following raw materials: bunge auriculate root, bamboo juice, Orobanche coerulescens, Ixeris chinensis, jasmine, red ginseng, fox heart, gastrodia elata, iron ore concentrate, bark of ash, Michelia fuscata, Euphorbia kansui,Chinese photinia leaf, cajeput, Aralia fargesii and girald daphne bark. The medicine provided by the invention is a pure traditional Chinese medicinal preparation. The selected medicinal materials are compatible with each other. The medicine provided by the invention is prepared by a modern advanced medical pharmaceutical technology, has functions of soothing the liver and resolving depression, nourishing the blood for tranquilization and keeping one's head to remove bother, has a good effect for adjuvant psychotherapy of neurasthenia, schizophrenia, depression and the like caused by various causes of disease, and has advantages of definite drug effect, short treatment course and fast effectiveness, and has no toxic or side effect. After recovery by the use of the medicine, diseases are not easy to relapse.
Acute myopia and secondary angle closure glaucoma have been reported in patients receiving ZONEGRAN. Elevated intraocular pressure can lead to serious sequelae, including permanent vision loss, if left untreated.  
  
Symptoms in reported cases have included acute onset of decreased visual acuity and/or ocular pain. Ophthalmologic findings can include myopia, anterior chamber shallowing, ocular hyperemia (redness), and increased intraocular pressure. Mydriasis may or may not be present. This syndrome may be associated with ciliochoroidal effusion resulting in anterior displacement of the lens and iris, with secondary angle closure glaucoma. Symptoms typically occur within one month after initiating ZONEGRAN therapy.  
  
In contrast to primary narrow angle glaucoma, which is rare under 40 years of age, secondary angle closure glaucoma associated with ZONEGRAN has been reported both in pediatric patients and in adults. The primary treatment to reverse symptoms is discontinuation of ZONEGRAN as rapidly as possible, according to the judgment of the treating physician. Other therapeutic measures, in conjunction with discontinuation of ZONEGRAN, may be helpful. Myopia and secondary angle closure glaucoma usually resolve or improve after discontinuation of ZONEGRAN.